Showing results (111-120 of 427) with videos related to

Sort By:
Pageof 43
Expert Review of Hematology|November 18, 2020
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practiceMassimo Breccia, Fabio Efficace, Gioia Colafigli, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 25, 2016
Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapiesFabio Efficace, Massimo Breccia, Francesco Cottone, et al.
Cancer Letters|January 8, 2013
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinibMassimo Breccia, Giuseppina Loglisci, Adriano Salaroli, et al.
Leukemia Research|August 3, 2013
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitorsFabio Efficace, Gianantonio Rosti, Francesco Cottone, et al.
British Journal of Haematology|July 26, 2002
Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?Massimo Breccia, Maria C Petti, Emanuela Ottaviani, et al.
Health and Quality of Life Outcomes|October 20, 2017
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patientsMassimo Breccia, Michele Baccarani, Gianantonio Rosti, et al.
Leukemia & Lymphoma|March 23, 2010
Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patientsMassimo Breccia, Roberto Latagliata, Laura Cannella, et al.
Pathologica|June 6, 2025
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusion: report of two cases with different clinical presentationElisabetta Merenda, Katia Paciaroni, Emilia Scalzulli, et al.
Leukemia Research|December 25, 2012
Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocolsMassimo Breccia, Clara Minotti, Roberto Latagliata, et al.
Frontiers in Oncology|August 8, 2024
Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectivesMassimo Breccia, Francesca Palandri, Nicola Polverelli, et al.
Pageof 43